Development and Validation of a Multiplex, Bead-based Assay to Detect Antibodies Directed Against SARS-CoV-2 Proteins.
Identifieur interne : 000083 ( Main/Exploration ); précédent : 000082; suivant : 000084Development and Validation of a Multiplex, Bead-based Assay to Detect Antibodies Directed Against SARS-CoV-2 Proteins.
Auteurs : Robert A. Bray [États-Unis] ; Jar-How Lee [États-Unis] ; Peter Brescia [États-Unis] ; Deepali Kumar [Canada] ; Thoa Nong [États-Unis] ; Remi Shih [États-Unis] ; E Steve Woodle [États-Unis] ; Jonathan S. Maltzman [États-Unis] ; Howard M. Gebel [États-Unis]Source :
- Transplantation [ 1534-6080 ] ; 2021.
Descripteurs français
- KwdFr :
- Anticorps antiviraux (sang), Dosage immunologique (MeSH), Glycoprotéine de spicule des coronavirus (immunologie), Humains (MeSH), Microparticules membranaires (immunologie), Réaction de polymérisation en chaine en temps réel (MeSH), Tests de criblage à haut débit (MeSH), Transplantation d'organe (MeSH), Trousses de réactifs pour diagnostic (MeSH).
- MESH :
English descriptors
- KwdEn :
- Antibodies, Viral (blood), COVID-19 (diagnosis), COVID-19 Serological Testing (MeSH), Cell-Derived Microparticles (immunology), Coronavirus Nucleocapsid Proteins (immunology), High-Throughput Screening Assays (MeSH), Humans (MeSH), Immunoassay (MeSH), Organ Transplantation (MeSH), Reagent Kits, Diagnostic (MeSH), Real-Time Polymerase Chain Reaction (MeSH), SARS-CoV-2 (immunology), Spike Glycoprotein, Coronavirus (immunology).
- MESH :
- chemical , blood : Antibodies, Viral.
- diagnosis : COVID-19.
- immunology : Cell-Derived Microparticles, Coronavirus Nucleocapsid Proteins, SARS-CoV-2, Spike Glycoprotein, Coronavirus.
- COVID-19 Serological Testing, High-Throughput Screening Assays, Humans, Immunoassay, Organ Transplantation, Reagent Kits, Diagnostic, Real-Time Polymerase Chain Reaction.
Abstract
BACKGROUND
Transplant recipients who develop COVID-19 may be at increased risk for morbidity and mortality. Determining the status of antibodies against SARS-CoV-2 in both candidates and recipients will be important to understand the epidemiology and clinical course of COVID-19 in this population. While there are multiple tests to detect antibodies to SARS-CoV-2, their performance is variable. Tests vary according to their platforms and the antigenic targets which make interpretation of the results challenging. Furthermore, for some assays, sensitivity and specificity are less than optimal. Additionally, currently available serological tests do not exclude the possibility that positive responses are due to cross reactive antibodies to community coronaviruses rather than SARS-CoV-2.
METHODS
This study describes the development and validation of a high-throughput multiplex antibody detection assay.
RESULTS
The multiplex assay has the capacity to identify, simultaneously, patient responses to 5 SARS-CoV-2 proteins, namely, the full spike protein, 3 individual domains of the spike protein (S1, S2, and receptor binding domain), and the nucleocapsid protein. The antibody response to the above proteins are SARS-CoV-2-specific, as antibodies against 4 common coronaviruses do not cross-react.
CONCLUSIONS
This new assay provides a novel tool to interrogate the spectrum of immune responses to SAR-CoV-2 and is uniquely suitable for use in the transplant setting. Test configuration is essentially identical to the single antigen bead assays used in the majority of histocompatibility laboratories around the world and could easily be implemented into routine screening of transplant candidates and recipients.
DOI: 10.1097/TP.0000000000003524
PubMed: 33273320
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Development and Validation of a Multiplex, Bead-based Assay to Detect Antibodies Directed Against SARS-CoV-2 Proteins.</title><author><name sortKey="Bray, Robert A" sort="Bray, Robert A" uniqKey="Bray R" first="Robert A" last="Bray">Robert A. Bray</name><affiliation wicri:level="2"><nlm:affiliation>Division of Laboratory Medicine, Department of Pathology, Emory University, Atlanta, GA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Géorgie (États-Unis)</region></placeName><wicri:cityArea>Division of Laboratory Medicine, Department of Pathology, Emory University, Atlanta</wicri:cityArea></affiliation></author><author><name sortKey="Lee, Jar How" sort="Lee, Jar How" uniqKey="Lee J" first="Jar-How" last="Lee">Jar-How Lee</name><affiliation wicri:level="2"><nlm:affiliation>Terasaki Innovation Center, Los Angeles, CA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Terasaki Innovation Center, Los Angeles</wicri:cityArea></affiliation></author><author><name sortKey="Brescia, Peter" sort="Brescia, Peter" uniqKey="Brescia P" first="Peter" last="Brescia">Peter Brescia</name><affiliation wicri:level="2"><nlm:affiliation>One Lambda Inc., Division of Thermo Fisher Scientific, West Hills, CA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>One Lambda Inc., Division of Thermo Fisher Scientific, West Hills</wicri:cityArea></affiliation></author><author><name sortKey="Kumar, Deepali" sort="Kumar, Deepali" uniqKey="Kumar D" first="Deepali" last="Kumar">Deepali Kumar</name><affiliation wicri:level="1"><nlm:affiliation>Transplant Infectious Diseases, Multi-Organ Transplant Program, University Health, Network, Toronto, ON, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Transplant Infectious Diseases, Multi-Organ Transplant Program, University Health, Network, Toronto, ON</wicri:regionArea><wicri:noRegion>ON</wicri:noRegion></affiliation></author><author><name sortKey="Nong, Thoa" sort="Nong, Thoa" uniqKey="Nong T" first="Thoa" last="Nong">Thoa Nong</name><affiliation wicri:level="2"><nlm:affiliation>One Lambda Inc., Division of Thermo Fisher Scientific, West Hills, CA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>One Lambda Inc., Division of Thermo Fisher Scientific, West Hills</wicri:cityArea></affiliation></author><author><name sortKey="Shih, Remi" sort="Shih, Remi" uniqKey="Shih R" first="Remi" last="Shih">Remi Shih</name><affiliation wicri:level="2"><nlm:affiliation>One Lambda Inc., Division of Thermo Fisher Scientific, West Hills, CA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>One Lambda Inc., Division of Thermo Fisher Scientific, West Hills</wicri:cityArea></affiliation></author><author><name sortKey="Woodle, E Steve" sort="Woodle, E Steve" uniqKey="Woodle E" first="E Steve" last="Woodle">E Steve Woodle</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Stanford University School of Medicine, Palo Alto, CA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Department of Medicine, Stanford University School of Medicine, Palo Alto</wicri:cityArea></affiliation></author><author><name sortKey="Maltzman, Jonathan S" sort="Maltzman, Jonathan S" uniqKey="Maltzman J" first="Jonathan S" last="Maltzman">Jonathan S. Maltzman</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Stanford University School of Medicine, Palo Alto, CA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Department of Medicine, Stanford University School of Medicine, Palo Alto</wicri:cityArea></affiliation><affiliation wicri:level="2"><nlm:affiliation>VA Palo Alto Health Care System, Palo Alto, CA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>VA Palo Alto Health Care System, Palo Alto</wicri:cityArea></affiliation></author><author><name sortKey="Gebel, Howard M" sort="Gebel, Howard M" uniqKey="Gebel H" first="Howard M" last="Gebel">Howard M. Gebel</name><affiliation wicri:level="2"><nlm:affiliation>Division of Laboratory Medicine, Department of Pathology, Emory University, Atlanta, GA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Géorgie (États-Unis)</region></placeName><wicri:cityArea>Division of Laboratory Medicine, Department of Pathology, Emory University, Atlanta</wicri:cityArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2021">2021</date><idno type="RBID">pubmed:33273320</idno><idno type="pmid">33273320</idno><idno type="doi">10.1097/TP.0000000000003524</idno><idno type="wicri:Area/Main/Corpus">000129</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000129</idno><idno type="wicri:Area/Main/Curation">000129</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000129</idno><idno type="wicri:Area/Main/Exploration">000129</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Development and Validation of a Multiplex, Bead-based Assay to Detect Antibodies Directed Against SARS-CoV-2 Proteins.</title><author><name sortKey="Bray, Robert A" sort="Bray, Robert A" uniqKey="Bray R" first="Robert A" last="Bray">Robert A. Bray</name><affiliation wicri:level="2"><nlm:affiliation>Division of Laboratory Medicine, Department of Pathology, Emory University, Atlanta, GA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Géorgie (États-Unis)</region></placeName><wicri:cityArea>Division of Laboratory Medicine, Department of Pathology, Emory University, Atlanta</wicri:cityArea></affiliation></author><author><name sortKey="Lee, Jar How" sort="Lee, Jar How" uniqKey="Lee J" first="Jar-How" last="Lee">Jar-How Lee</name><affiliation wicri:level="2"><nlm:affiliation>Terasaki Innovation Center, Los Angeles, CA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Terasaki Innovation Center, Los Angeles</wicri:cityArea></affiliation></author><author><name sortKey="Brescia, Peter" sort="Brescia, Peter" uniqKey="Brescia P" first="Peter" last="Brescia">Peter Brescia</name><affiliation wicri:level="2"><nlm:affiliation>One Lambda Inc., Division of Thermo Fisher Scientific, West Hills, CA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>One Lambda Inc., Division of Thermo Fisher Scientific, West Hills</wicri:cityArea></affiliation></author><author><name sortKey="Kumar, Deepali" sort="Kumar, Deepali" uniqKey="Kumar D" first="Deepali" last="Kumar">Deepali Kumar</name><affiliation wicri:level="1"><nlm:affiliation>Transplant Infectious Diseases, Multi-Organ Transplant Program, University Health, Network, Toronto, ON, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Transplant Infectious Diseases, Multi-Organ Transplant Program, University Health, Network, Toronto, ON</wicri:regionArea><wicri:noRegion>ON</wicri:noRegion></affiliation></author><author><name sortKey="Nong, Thoa" sort="Nong, Thoa" uniqKey="Nong T" first="Thoa" last="Nong">Thoa Nong</name><affiliation wicri:level="2"><nlm:affiliation>One Lambda Inc., Division of Thermo Fisher Scientific, West Hills, CA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>One Lambda Inc., Division of Thermo Fisher Scientific, West Hills</wicri:cityArea></affiliation></author><author><name sortKey="Shih, Remi" sort="Shih, Remi" uniqKey="Shih R" first="Remi" last="Shih">Remi Shih</name><affiliation wicri:level="2"><nlm:affiliation>One Lambda Inc., Division of Thermo Fisher Scientific, West Hills, CA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>One Lambda Inc., Division of Thermo Fisher Scientific, West Hills</wicri:cityArea></affiliation></author><author><name sortKey="Woodle, E Steve" sort="Woodle, E Steve" uniqKey="Woodle E" first="E Steve" last="Woodle">E Steve Woodle</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Stanford University School of Medicine, Palo Alto, CA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Department of Medicine, Stanford University School of Medicine, Palo Alto</wicri:cityArea></affiliation></author><author><name sortKey="Maltzman, Jonathan S" sort="Maltzman, Jonathan S" uniqKey="Maltzman J" first="Jonathan S" last="Maltzman">Jonathan S. Maltzman</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Stanford University School of Medicine, Palo Alto, CA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Department of Medicine, Stanford University School of Medicine, Palo Alto</wicri:cityArea></affiliation><affiliation wicri:level="2"><nlm:affiliation>VA Palo Alto Health Care System, Palo Alto, CA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>VA Palo Alto Health Care System, Palo Alto</wicri:cityArea></affiliation></author><author><name sortKey="Gebel, Howard M" sort="Gebel, Howard M" uniqKey="Gebel H" first="Howard M" last="Gebel">Howard M. Gebel</name><affiliation wicri:level="2"><nlm:affiliation>Division of Laboratory Medicine, Department of Pathology, Emory University, Atlanta, GA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Géorgie (États-Unis)</region></placeName><wicri:cityArea>Division of Laboratory Medicine, Department of Pathology, Emory University, Atlanta</wicri:cityArea></affiliation></author></analytic><series><title level="j">Transplantation</title><idno type="eISSN">1534-6080</idno><imprint><date when="2021" type="published">2021</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibodies, Viral (blood)</term><term>COVID-19 (diagnosis)</term><term>COVID-19 Serological Testing (MeSH)</term><term>Cell-Derived Microparticles (immunology)</term><term>Coronavirus Nucleocapsid Proteins (immunology)</term><term>High-Throughput Screening Assays (MeSH)</term><term>Humans (MeSH)</term><term>Immunoassay (MeSH)</term><term>Organ Transplantation (MeSH)</term><term>Reagent Kits, Diagnostic (MeSH)</term><term>Real-Time Polymerase Chain Reaction (MeSH)</term><term>SARS-CoV-2 (immunology)</term><term>Spike Glycoprotein, Coronavirus (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Anticorps antiviraux (sang)</term><term>Dosage immunologique (MeSH)</term><term>Glycoprotéine de spicule des coronavirus (immunologie)</term><term>Humains (MeSH)</term><term>Microparticules membranaires (immunologie)</term><term>Réaction de polymérisation en chaine en temps réel (MeSH)</term><term>Tests de criblage à haut débit (MeSH)</term><term>Transplantation d'organe (MeSH)</term><term>Trousses de réactifs pour diagnostic (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Glycoprotéine de spicule des coronavirus</term><term>Microparticules membranaires</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Cell-Derived Microparticles</term><term>Coronavirus Nucleocapsid Proteins</term><term>SARS-CoV-2</term><term>Spike Glycoprotein, Coronavirus</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antiviraux</term></keywords><keywords scheme="MESH" xml:lang="en"><term>COVID-19 Serological Testing</term><term>High-Throughput Screening Assays</term><term>Humans</term><term>Immunoassay</term><term>Organ Transplantation</term><term>Reagent Kits, Diagnostic</term><term>Real-Time Polymerase Chain Reaction</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Dosage immunologique</term><term>Humains</term><term>Réaction de polymérisation en chaine en temps réel</term><term>Tests de criblage à haut débit</term><term>Transplantation d'organe</term><term>Trousses de réactifs pour diagnostic</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>Transplant recipients who develop COVID-19 may be at increased risk for morbidity and mortality. Determining the status of antibodies against SARS-CoV-2 in both candidates and recipients will be important to understand the epidemiology and clinical course of COVID-19 in this population. While there are multiple tests to detect antibodies to SARS-CoV-2, their performance is variable. Tests vary according to their platforms and the antigenic targets which make interpretation of the results challenging. Furthermore, for some assays, sensitivity and specificity are less than optimal. Additionally, currently available serological tests do not exclude the possibility that positive responses are due to cross reactive antibodies to community coronaviruses rather than SARS-CoV-2.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>This study describes the development and validation of a high-throughput multiplex antibody detection assay.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>The multiplex assay has the capacity to identify, simultaneously, patient responses to 5 SARS-CoV-2 proteins, namely, the full spike protein, 3 individual domains of the spike protein (S1, S2, and receptor binding domain), and the nucleocapsid protein. The antibody response to the above proteins are SARS-CoV-2-specific, as antibodies against 4 common coronaviruses do not cross-react.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>This new assay provides a novel tool to interrogate the spectrum of immune responses to SAR-CoV-2 and is uniquely suitable for use in the transplant setting. Test configuration is essentially identical to the single antigen bead assays used in the majority of histocompatibility laboratories around the world and could easily be implemented into routine screening of transplant candidates and recipients.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33273320</PMID><DateCompleted><Year>2021</Year><Month>01</Month><Day>06</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1534-6080</ISSN><JournalIssue CitedMedium="Internet"><Volume>105</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>01</Month><Day>01</Day></PubDate></JournalIssue><Title>Transplantation</Title><ISOAbbreviation>Transplantation</ISOAbbreviation></Journal><ArticleTitle>Development and Validation of a Multiplex, Bead-based Assay to Detect Antibodies Directed Against SARS-CoV-2 Proteins.</ArticleTitle><Pagination><MedlinePgn>79-89</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/TP.0000000000003524</ELocationID><Abstract><AbstractText Label="BACKGROUND">Transplant recipients who develop COVID-19 may be at increased risk for morbidity and mortality. Determining the status of antibodies against SARS-CoV-2 in both candidates and recipients will be important to understand the epidemiology and clinical course of COVID-19 in this population. While there are multiple tests to detect antibodies to SARS-CoV-2, their performance is variable. Tests vary according to their platforms and the antigenic targets which make interpretation of the results challenging. Furthermore, for some assays, sensitivity and specificity are less than optimal. Additionally, currently available serological tests do not exclude the possibility that positive responses are due to cross reactive antibodies to community coronaviruses rather than SARS-CoV-2.</AbstractText><AbstractText Label="METHODS">This study describes the development and validation of a high-throughput multiplex antibody detection assay.</AbstractText><AbstractText Label="RESULTS">The multiplex assay has the capacity to identify, simultaneously, patient responses to 5 SARS-CoV-2 proteins, namely, the full spike protein, 3 individual domains of the spike protein (S1, S2, and receptor binding domain), and the nucleocapsid protein. The antibody response to the above proteins are SARS-CoV-2-specific, as antibodies against 4 common coronaviruses do not cross-react.</AbstractText><AbstractText Label="CONCLUSIONS">This new assay provides a novel tool to interrogate the spectrum of immune responses to SAR-CoV-2 and is uniquely suitable for use in the transplant setting. Test configuration is essentially identical to the single antigen bead assays used in the majority of histocompatibility laboratories around the world and could easily be implemented into routine screening of transplant candidates and recipients.</AbstractText><CopyrightInformation>Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bray</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Division of Laboratory Medicine, Department of Pathology, Emory University, Atlanta, GA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Jar-How</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Terasaki Innovation Center, Los Angeles, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brescia</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>One Lambda Inc., Division of Thermo Fisher Scientific, West Hills, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Deepali</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Transplant Infectious Diseases, Multi-Organ Transplant Program, University Health, Network, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nong</LastName><ForeName>Thoa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>One Lambda Inc., Division of Thermo Fisher Scientific, West Hills, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shih</LastName><ForeName>Remi</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>One Lambda Inc., Division of Thermo Fisher Scientific, West Hills, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woodle</LastName><ForeName>E Steve</ForeName><Initials>ES</Initials><AffiliationInfo><Affiliation>Department of Medicine, Stanford University School of Medicine, Palo Alto, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maltzman</LastName><ForeName>Jonathan S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Department of Medicine, Stanford University School of Medicine, Palo Alto, CA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VA Palo Alto Health Care System, Palo Alto, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gebel</LastName><ForeName>Howard M</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Division of Laboratory Medicine, Department of Pathology, Emory University, Atlanta, GA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Transplantation</MedlineTA><NlmUniqueID>0132144</NlmUniqueID><ISSNLinking>0041-1337</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086462">Coronavirus Nucleocapsid Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011933">Reagent Kits, Diagnostic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000087124" MajorTopicYN="N">COVID-19 Serological Testing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055252" MajorTopicYN="N">Cell-Derived Microparticles</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086462" MajorTopicYN="N">Coronavirus Nucleocapsid Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057166" MajorTopicYN="N">High-Throughput Screening Assays</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007118" MajorTopicYN="N">Immunoassay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016377" MajorTopicYN="N">Organ Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011933" MajorTopicYN="N">Reagent Kits, Diagnostic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060888" MajorTopicYN="N">Real-Time Polymerase Chain Reaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>J.-H.L. is a consultant to One Lambda Inc., a division of Thermo-Fisher Scientific. P.B., T.N., and R.S. are employees of One Lambda Inc., a division of Thermo-Fisher Scientific. R.A.B. is a member of the Scientific Advisory Board for Luminex. R.A.B. and H.M.G. have received honoraria from Thermo-Fisher for presenting CME certified lectures. The other authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>12</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>1</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>12</Month><Day>4</Day><Hour>5</Hour><Minute>38</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33273320</ArticleId><ArticleId IdType="pii">00007890-202101000-00016</ArticleId><ArticleId IdType="doi">10.1097/TP.0000000000003524</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Li Z, Yi Y, Luo X, et al. Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. J Med Virol. 2020;92:1518–1524.</Citation></Reference><Reference><Citation>Du Z, Zhu F, Guo F, et al. Detection of antibodies against SARS-CoV-2 in patients with COVID-19. J Med Virol. 2020;92:1735–1738.</Citation></Reference><Reference><Citation>Nie J, Li Q, Wu J, et al. Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. Emerg Microbes Infect. 2020;9:680–686.</Citation></Reference><Reference><Citation>Ward S, Lindsley A, Courter J, et al. Clinical testing for COVID-19. J Allergy Clin Immunol. 2020;146:23–34.</Citation></Reference><Reference><Citation>Zeng W, Liu G, Ma H, et al. Biochemical characterization of SARS-CoV-2 nucleocapsid protein. Biochem Biophys Res Commun. 2020;527:618–623.</Citation></Reference><Reference><Citation>Cai Y, Zhang J, Xiao T, et al. Distinct conformational states of SARS-CoV-2 spike protein. Science. 2020;369:1586–1592.</Citation></Reference><Reference><Citation>Lan J, Ge J, Yu J, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020;581:215–220.</Citation></Reference><Reference><Citation>French MA, Moodley Y. The role of SARS-CoV-2 antibodies in COVID-19: Healing in most, harm at times. Respirology. 2020;25:680–682.</Citation></Reference><Reference><Citation>Kumleben N, Bhopal R, Czypionka T, et al. Test, test, test for COVID-19 antibodies: the importance of sensitivity, specificity and predictive powers. Public Health. 2020;185:88–90.</Citation></Reference><Reference><Citation>Deeks JJ, Dinnes J, Takwoingi Y, et al.; Cochrane COVID-19 Diagnostic Test Accuracy Group. Antibody tests for identification of current and past infection with SARS-CoV-2. Cochrane Database Syst Rev. 2020;6:CD013652</Citation></Reference><Reference><Citation>Weisberg SP, Connors T, Zhu Y, et al. Distinct antibody responses to SArSA-CoV-2 in children and adults across the COVID-19 clinical spectrum. Nat Immunol. [Epub ahead of print. November 5, 2020]. doi:10.1038/s41590-020-00826-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-020-00826-9.</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson S, Hirsch JS, Narasimhan M, et al.; the Northwell COVID-19 Research Consortium. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323:2052–2059.</Citation></Reference><Reference><Citation>Benotmane I, Perrin P, Gautier Vargas G, et al. Biomarkers of cytokine release syndrome predict disease severity and mortality from COVID-19 in kidney transplant recipients [Epub ahead of print. September 30, 2020]. Transplantation. doi: 10.1097/TP.0000000000003480</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/tp.0000000000003480</ArticleId></ArticleIdList></Reference><Reference><Citation>Malekhosseini SA, Nikoupour H, Gholami, et al. A report of 85 cases of covid-19 and abdominal transplantation from a single center: what are the associated factors with death among organ transplantation patients. Transplantation. 2021;105:90–99.</Citation></Reference><Reference><Citation>Cravedi P, Suraj SM, Azzi Y, et al. COVID-19 and kidney transplantation: results from the TANGO International Transplant Consortium [Epub ahead of print. July 10, 2020]. Am J Transplant. doi: 10.1111/ajt.16185</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ajt.16185</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira MR, Mohan S, Cohen DJ, et al. COVID-19 in solid organ transplant recipients: Initial report from the US epicenter. Am J Transplant. 2020;20:1800–1808.</Citation></Reference><Reference><Citation>Gebel HM, Bray RA. HLA antibody detection with solid phase assays: great expectations or expectations too great? Am J Transplant. 2014;14:1964–1975.</Citation></Reference><Reference><Citation>Morris AB, Sullivan HC, Krummey SM, et al. Out with the old, in with the new: Virtual versus physical crossmatching in the modern era. HLA. 2019;94:471–481.</Citation></Reference><Reference><Citation>Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367:1260–1263.</Citation></Reference><Reference><Citation>Jaimes JA, André NM, Chappie JS, et al. Phylogenetic analysis and structural modeling of SARS-CoV-2 spike protein reveals an evolutionary distinct and proteolytically sensitive activation loop. J Mol Biol. 2020;432:3309–3325.</Citation></Reference><Reference><Citation>Bloch EM, Shoham S, Casadevall A, et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest. 2020;130:2757–2765.</Citation></Reference><Reference><Citation>Suthar MS, Zimmerman MG, Kauffman RC, et al. Rapid generation of neutralizing antibody responses in COVID-19 patients. Cell Rep Med. 2020;1:100040</Citation></Reference><Reference><Citation>Chi X, Yan R, Zhang J, et al. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science. 2020;369:650–655.</Citation></Reference><Reference><Citation>Yoshimoto FK. The proteins of severe acute respiratory syndrome coronavirus-2 (SARS CoV-2 or n-COV19), the cause of COVID-19. Protein J. 2020;39:198–216.</Citation></Reference><Reference><Citation>Ayouba A, Thaurignac G, Morquin D, et al. Multiplex detection and dynamics of IgG antibodies to SARS-CoV2 and the highly pathogenic human coronaviruses SARS-CoV and MERS-CoV. J Clin Virol. 2020;129:104521</Citation></Reference><Reference><Citation>Jiang HW, Li Y, Zhang HN, et al. SARS-CoV-2 proteome microarray for global profiling of COVID-19 specific IgG and IgM responses. Nat Commun. 2020;11:3581</Citation></Reference><Reference><Citation>Padilla-Quirarte HO, Lopez-Guerrero DV, Gutierrez-Xicotencatl L, et al. Protective antibodies against influenza proteins. Front Immunol. 2019;10:1677</Citation></Reference><Reference><Citation>Fang Y, Banner D, Kelvin AA, et al. Seasonal H1N1 influenza virus infection induces cross-protective pandemic H1N1 virus immunity through a CD8-independent, B cell-dependent mechanism. J Virol. 2012;86:2229–2238.</Citation></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Canada</li><li>États-Unis</li></country><region><li>Californie</li><li>Géorgie (États-Unis)</li></region></list><tree><country name="États-Unis"><region name="Géorgie (États-Unis)"><name sortKey="Bray, Robert A" sort="Bray, Robert A" uniqKey="Bray R" first="Robert A" last="Bray">Robert A. Bray</name></region><name sortKey="Brescia, Peter" sort="Brescia, Peter" uniqKey="Brescia P" first="Peter" last="Brescia">Peter Brescia</name><name sortKey="Gebel, Howard M" sort="Gebel, Howard M" uniqKey="Gebel H" first="Howard M" last="Gebel">Howard M. Gebel</name><name sortKey="Lee, Jar How" sort="Lee, Jar How" uniqKey="Lee J" first="Jar-How" last="Lee">Jar-How Lee</name><name sortKey="Maltzman, Jonathan S" sort="Maltzman, Jonathan S" uniqKey="Maltzman J" first="Jonathan S" last="Maltzman">Jonathan S. Maltzman</name><name sortKey="Maltzman, Jonathan S" sort="Maltzman, Jonathan S" uniqKey="Maltzman J" first="Jonathan S" last="Maltzman">Jonathan S. Maltzman</name><name sortKey="Nong, Thoa" sort="Nong, Thoa" uniqKey="Nong T" first="Thoa" last="Nong">Thoa Nong</name><name sortKey="Shih, Remi" sort="Shih, Remi" uniqKey="Shih R" first="Remi" last="Shih">Remi Shih</name><name sortKey="Woodle, E Steve" sort="Woodle, E Steve" uniqKey="Woodle E" first="E Steve" last="Woodle">E Steve Woodle</name></country><country name="Canada"><noRegion><name sortKey="Kumar, Deepali" sort="Kumar, Deepali" uniqKey="Kumar D" first="Deepali" last="Kumar">Deepali Kumar</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidStanfordV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000083 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000083 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidStanfordV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:33273320
|texte= Development and Validation of a Multiplex, Bead-based Assay to Detect Antibodies Directed Against SARS-CoV-2 Proteins.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:33273320" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidStanfordV1
| This area was generated with Dilib version V0.6.38. |  |